BUSINESS COMBINATION (Details 4) (USD $)	12 Months Ended		24 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jun. 19, 2013
Share Price				$ 1.22
Revenues, Total	$ 30,082,000	$ 20,371,000
Business Combination Cost Of Acquired Entity Purchase Price	29,800,000		29,800,000	29,795,000
Business Combination Deferred Tax Assets Established Gross	9,600,000		9,600,000
Business Combination Deferred Tax Liabilities Established Gross	3,900,000		3,900,000
Valuation allowance	5,700,000		5,700,000
Business Combination Purchase Price Allocation Deferred Tax Assets, Net	0		0	0
Business Combination, Acquisition Related Costs	6,200,000	900,000	7,100,000
Selling, General and Administrative Expenses [Member]
Business Combination, Acquisition Related Costs	5,500,000
Interest Expense [Member]
Business Combination, Acquisition Related Costs	300,000
Other Expense [Member]
Business Combination, Acquisition Related Costs	400,000
Teva License Intangible Asset [Member]
Finite-Lived Intangible Asset, Useful Life	11 years
BioSante Pharmaceuticals Inc [Member]
Business Acquisition, Percentage of Voting Interests Acquired				43.00%
Revenues, Total	$ 500
ANIP Acquisition Company [Member]
Business Acquisition, Percentage of Voting Interests Acquired				57.00%